Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Asaretoclax in Chinese subjects with Non-Hodgkin Lymphoma
NCT05127811Phase 1Terminated
- Sponsor
- Zentera Therapeutics
- Start
- Oct 2021
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of asaretoclax in non-Hodgkin lymphoma (NHL) (6 arms), sponsored by Zentera Therapeutics. Primary endpoints: Safety monitoring and Dose Limiting Toxicity at Cycle 1. Started Oct 2021; status: terminated.
02
Drugs
asaretoclax
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05127811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05127811.